Lanreotide Completed Phase 4 Trials for Neuroendocrine Tumour (NET) With Carcinoid Syndrome Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00681187Somatuline Autogel Preference and Health Economy Study